Testing remibrutinib vs dupilumab for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study compares two oral medications, remibrutinib and dupilumab, to see which works faster for chronic hives that don't get better with standard antihistamines. You may be eligible if you have had hives and itching for at least 6 months and they are still active despite daily antihistamines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had hives and itching for at least 6 months
- Your hives and itching have been active for at least 6 weeks in a row before the study starts, even while taking antihistamines
- You are willing to fill out a daily diary about your hives and itching
- You have not taken remibrutinib or dupilumab before
- You do not have serious heart, liver, bleeding, or other major health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
This study tests whether a new drug called MG-K10 can help people with chronic hives (itchy welts) that haven't improved with standard allergy medications. MG-K10 works differently than regular allergy pills, targeting a specific immune pathway that causes hives.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.